New hope for cancer patients: drug may ease painful skin rashes

NCT ID NCT04552288

First seen Apr 16, 2026 · Last updated May 08, 2026 · Updated 2 times

Summary

This study tests if benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. About 51 adults with solid tumors or blood cancers who have moderate to severe skin side effects will receive the drug. The goal is to lower blood eosinophil levels, ease symptoms, and help patients stay on their cancer therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities)

    Hauppauge, New York, 11788, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.